Over 76 Data Driven Presentations on Cancer Treatment Research to be Presented at the 9th Annual World Antibody-Drug Conjugate Conference in San Diego, November 12-15

SAN DIEGO, CA , --The Antibody-Drug Conjugate community will join together for the 9th World ADC San Diego on November 12-15 at the Marriott Marquis San Diego with key influential researchers from around the world, to discuss clinical research experiences to help further the development of cancer therapeutics. The conference is expected to draw over 600 industry stakeholders, and will feature over 60 scientific posters on the top innovations in ADC science within the past year, and over 70 presentations from key speakers.   Research presented this year shows how the scientific community continues to harness new technologies and insights to improve upon and develop more effective cancer treatments. These include: ADCs outside of oncology, payloads with novel mechanisms of action such as non-cytotoxic payloads and ADC/Immuno-oncology combinations to name but a few.

According to Fiona Mistri, Program Director, World ADC: “As the industry’s longest standing and most comprehensive antibody-drug conjugate conference, World ADC San Diego is the definitive opportunity for researchers and developers to gain and utilize key learnings in an open environment of knowledge sharing and exchange.”

Over the past nine years, the ADC conference has continued to gain momentum and draw key researchers and scientists from Fortune 500 companies and highly recognizable research institutions.


Key Scientific Poster Presentations Include:


  • Genentech,  - “Generation of a THIOMABTM Antibody XTEN Conjugate (TXC)” - Neelie Zacharias, Scientific Manager (4:30pm Tuesday, November 13)
  • ImmunoGen - “Evaluation of an Imaged Capillary Isoelectric Focusing (icIEF) Method for a Lysine Linked Antibody- Drug Conjugate (ADC) using Maurice” - Morgan Rudick, Associate Scientist II (4:30pm Tuesday, November 13)
  • MedImmune - “Identification of a Novel PBD Dimer with Increased Conjugation Efficiency & Decreased P-gp Susceptibility” - Shenlan Mao, Scientist (4:30pm Tuesday, November 13)
  • Pharmamar – “MI180021: A Novel ADC with a New Marine DNA Binder Payload” - Carman Cuevas, Director, Research & Development (4:30pm Tuesday, November 13)


Key Speakers Presentations Include:


  • Genentech: “Unveiling Complex & Novel Biotransformations of Antibody Drug Conjugates Bearing CBI Dimer Payloads” Dian Su, Scientist, (10:30am, Tuesday November 13, Location: Discovery Stream)
  • Novartis: “From Bench to Bedside & Back Again: The Development of a c-KIT ADC, Tinya Abrams, Senior Investigator, (2.30pm Tuesday November 13, Location: Clinical Stream)
  • ImmunoGen: “Lessons Learned from Developing Processes for Late Stage Clinical Development”, Richard Silva, Senior Director, Process Development, CMC (11:00am Tuesday November 13, Location: CMC Stream)
  • MedImmune: “Disulfide Re-Bridging with Pyrrolobenzodiazepine Dimers Enable the Formation of Homogeneous, Potent & Differentiated Antibody & Fab Drug Conjugates, Nazzareno Dimasi, Associate Director, Research & Development (2:00pm Wednesday November 14, Location: Discovery Stream)
  • Bristol Myers Squibb: “Harnessing Multiscale Modelling to Optimize Design of Antibody Drug Conjugates for Clinical Success”, Renu Singh Dhanikula, Senior Investigator (2:00pm November 14, Location: Translational Stream)
  • Translational Sciences: “Development & Execution of a Diagnostics Strategy for Patient Analyses & Stratification for a Probody Drug Conjugate (PDC)”, Luc Desnoyers, Senior Director, CytomX (11:00am, November 14, Location: Clinical Stream).


The full agenda can be viewed at http://worldadc-usa.com/program/full-event-guide/.

About Antibody-drug Conjugate Therapies:

Antibody-drug conjugates (ADCs) are effective biological drugs designed to treat cancer in a more targeted manner and are at the forefront of oncology therapeutics.  ADCs are complex molecules which harness an antibody (to search out the disease) with an anti-cancer agent such as a payload or drug (to kill the cancer). This enables the cancer cells to be targeted effectively without damage to other, healthy cells.

There is continued enthusiasm for antibody-drug conjugates (ADCs) as a cornerstone in cancer treatment. Currently there are 4 approved ADCs (Mylotarg (Pfizer), Besponsa (Pfizer), Kadcyla (Genentech/Roche) and Adcetris (Seattle Genetics/Takeda)) and 81+ in clinical development. In the last few months there have been more promising clinical results for ADCs such as Sacituzumab govitecan (Immunomedics) and DS-8201 (Daiichi Sankyo).

New areas such as novel ADC technologies (payloads, linkers, antibody engineering), ADCs and immuno-oncology and ADCs outside of oncology are all bringing renewed momentum to the space.

World ADC:

World ADC is the industry’s definitive forum for learning and networking. www.worldadc-usa.com.  World ADC San Diego will feature its Scientific Poster session (Monday November 12) with 60+ scientific posters. As part of the conference, the 5th Annual World ADC Awards (Tuesday November 13) will recognize the extraordinary endeavours, teamwork and commercial acumen that has propelled the field to the forefront of cancer research today.

“World ADC San Diego will once again to be the environment in which scientists can communicate problems and solutions; share novel data and forge networks to develop more clinically impactful ADCs.”  For more information please visit http://worldadc-usa.com/.


Senior Partners

Ajinomoto Bio-Pharma Services


Heidelberg Pharma






Seattle Genetics


Back to news